Evidence map›Paper›PMID 36111122›Full record

ArticleFrontiers in medicine2022

Implemented occupational health surveillance limits the spread of SARS-CoV-2 Omicron at the workplace.

João Silveira Moledo Gesto, Adriana Cabanelas, Bruna Farjun, Monique Cristina Dos Santos, Antonio A Fidalgo-Neto, Sergio N Kuriyama, Thiago Moreno L Souza

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

João Silveira Moledo GestoSESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil.
Adriana CabanelasSESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil.
Bruna FarjunSESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil.
Monique Cristina Dos SantosLaboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Antonio A Fidalgo-NetoSENAI Innovation Institute for Green Chemistry, Rio de Janeiro, Brazil.
Sergio N KuriyamaSESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil.
Thiago Moreno L SouzaSESI Innovation Center for Occupational Health, Rio de Janeiro, Brazil.
Fundação Oswaldo Cruz · BRServiço Nacional de Aprendizagem Industrial · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has put an enormous pressure on human societies, at both health and economic levels. Early diagnosis of SARS-CoV-2, the causative agent of 2019 coronavirus disease (COVID-19), has proved an efficient method to rapidly isolate positive individuals and reduce transmission rates, thus alleviating its negative impact on society's well-being and economic growth. In this work, through a coordinated and centralized effort to monitor SARS-CoV-2 circulation in companies from the State of Rio de Janeiro, Brazil, we have detected and linked an early rise of infection rates in January 2022 to the introduction of the Omicron variant of concern (VoC) (BA.1). Interestingly, when the Omicron genomic isolates were compared to correlates from public datasets, it was revealed that introduction events were multiple, with possible migration routes mapping to: Mali; Oman and United States; and Italy, Latin America, and United States. In addition, we have built a haplotype network with our genomic dataset and found no strong evidence of transmission chains, between and within companies. Considering Omicron's particularly high transmissibility, and that most of our samples (>87%) arose from 3 out of 10 companies, these findings suggest that workers from such environments were exposed to SARS-CoV-2 outside their company boundaries. Thus, using a mixed strategy in which quick molecular diagnosis finds support in comprehensive genomic analysis, we have shown that a successfully implemented occupational health program should contribute to document emerging VoC and to limit the spread of SARS-CoV-2 at the workplace.

Indexed as

COVID-19genomic surveillancenext generation sequencing – NGSoccupational healthSARS-CoV-2

Identifiers

PMID36111122
PMCPMC9468326
OpenAlexW4293538869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.